ONERA-HEALTH
3.1.2022 16:02:10 CET | Business Wire | Press release
Onera Health announced today the introduction of its first Onera Biomedical-Lab-on-Chip™. The biomedical sensor system-on-chip acquires and processes multiple biosignals and is designed for a broad range of wearable health applications and devices, offering many solutions and opportunities for innovation in the medical, wellness and fitness space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005188/en/
"We are thrilled to introduce Onera Biomedical-Lab-on-Chip™ in the lead-up to CES 2022 in Las Vegas this week. It's the perfect opportunity to showcase our chip to the wearables ecosystem! Our highly integrated and comprehensive biosignal sensor hub is a unique solution that promises to revolutionize this competitive field. It combines clinical-grade physiological measurements and analysis with ultra-low-power consumption, enabling the development of miniaturized and high-quality wearable devices. Launching this powerful chip as a stand-alone product within our portfolio, not just as part of our innovative Onera diagnostic and monitoring solutions, is yet another exciting step for our company", explains Ruben de Francisco, Founder and CEO of Onera.
The Dutch-American company leveraged from its deep tech roots and close partnership with imec, a world-leading research and innovation hub in nanoelectronics and digital technologies, with the development of the ultra-low-power biosignal chip.
“Seeing Onera bring this ground-breaking system-on-chip to the market is what imec’s unique experience in semiconductor devices for MedTech applications, and our imec ecosystem, is all about - enabling nano- and digital technology innovation that promises a significant impact on the quality of life”, added Rudi Cartuyvels, COO of imec.
Onera Biomedical-Lab-on-Chip™ is a multi-channel sensor readout system with integrated data processing, power management, and interfacing features. It offers a wide range of on-chip biomedical sensor readouts, including 10 readouts for ExG, covering EEG, ECG, EMG, and EOG, 2 bioimpedance readouts, and 2 readouts for photoplethysmography. The data can be processed by on-chip digital filters and accelerators, supported by a powerful ARM Cortex M4f. The chip features several standard wired interfaces such as UART, SPI, I2C, and I2S. The chip fully operates on a single power source which can be anything between 0.8V and 3.6V, since power management is also integrated on-chip. In addition, a large amount of SRAM and embedded FLASH is available, supporting the large number of data streams with accurate data-synchronization as an essential feature.
To support the development and transition to commercialization of Onera’s products, the company has ramped-up hiring recently, including adding to its strong leadership team.
From the 5th to the 8th of January 2022, Onera Health exhibits its Onera STS I Polysomnography Solution and its Onera Biomedical-Lab-on-Chip™ at CES 2022 in Las Vegas, booth 8570 in the LVCC - North Hall.
About Onera
Onera Health is a leader in transforming diagnostics and monitoring. Their breakthrough products and technologies are poised to help millions of people struggling with health ailments and chronic conditions in a variety of medical fields, including sleep, neuro, cardiac and respiratory care, ultimately improving the health and quality of life for patients around the world. The company’s innovative solutions provide comprehensive physiological and health-related data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the US. For more information, go to www.onerahealth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005188/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newmont Reports 2025 Mineral Reserves of 118.2 Million Gold Ounces and 12.5 Million Tonnes of Copper19.2.2026 22:08:00 CET | Press release
Newmont Corporation (NYSE: NEM, ASX: NGT, PNGX: NEM) (Newmont or the Company) reported gold Mineral Reserves ("reserves") of 118.2 million attributable ounces at the end of 2025 compared to 134.1 million attributable ounces at the end of 2024, mainly driven by the divestment of assets in 2025. Newmont's portfolio includes significant reserves from other metals, including 12.5 million attributable tonnes of copper reserves and 442 million attributable ounces of silver reserves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219894602/en/ Percentage of Gold Reserves by Jurisdiction "In 2025, Newmont maintained its position of having the industry's largest gold reserve base, declaring 118 million ounces of reserves, representing decades of production life with meaningful upside," said Natascha Viljoen, Newmont's President and Chief Executive Officer. "Through the disciplined application of technical rigor in our leading expl
Unveiling NVIDIA Solution Center: Grid Dynamics’ Family of AI Solutions to Cut Costs for Retail and Manufacturing19.2.2026 22:05:00 CET | Press release
Key Takeaways: Enables enterprises to replace high-cost and recurring SaaS licensing fees with high-performance and cost-efficient NVIDIA-based solutions Offerings are derived from Grid Dynamics’ proven customer solutions and leverage NVIDIA’s technology stack Commercially deployed, with additional customers expressing interest NVIDIA and Grid Dynamics jointly presented these solutions at the National Retail Federation (NRF) conference in January 2026 Learn more in NVIDIA’s published blog Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics), a premier AI transformation partner for the Fortune 1000, today announced the launch of its NVIDIA Solution Center. This suite of ready-to-deploy AI applications helps retail and manufacturing enterprises move away from costly, recurring SaaS licenses and subscription fees toward high-performance, NVIDIA-powered solutions. Learn more by reading NVIDIA’s recent announcement. The NVIDIA Solution Center is derived from Grid Dynamics’ proven suc
Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results19.2.2026 22:01:00 CET | Press release
Fourth Quarter and Full Year 2025 Financial Highlights Include:Remaining Performance Obligations (RPO) of $652.9 million, up 11.1% from the prior yearAdjusted Calculated Billings, full year 2025, up 4.2% from the prior yearAdjusted Annualized Recurring Revenue (ARR) up 3.1% from the prior year Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the 2025 fourth quarter and fiscal year ended December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219293814/en/ Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results “Our fourth quarter results reflect solid execution and continued accelerating sales growth, adjusted for the Oracle PeopleSoft support and services wind
Ares Management Prices European Direct Lending CLO II at Over €300 Million19.2.2026 18:25:00 CET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely of directly originated and actively managed loans issued by over 70 middle-market companies predominantly based in Western Europe and primarily operating in resilient industries. The instrument is weighted towards senior-secured floating rate loans and will be rated by S&P and KBRA. Ares believes EDL CLO II is among the first multi-currency middle-market CLOs in Europe. “We are pleased to successfully price our second European Direct Lending CLO in less than 12 months as we continue building on our nearly 20 years of corporate direct lending experience in Europe,” said Michael Dennis, Partner and Co-Head of
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis19.2.2026 18:00:00 CET | Press release
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly half (47.3%) of randomized patients achieved primary endpoint of clinical remission at 54 weeksVedolizumab’s safety profile was generally consistent with its known safety profile in adultsResults were presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
